The August 2026 acne update is modest: no major new U.S. acne approval is documented for the month.
The meaningful developments are recent enforcement against unsupported product claims, limited isotretinoin research, and an early laser study—not a new standard of care. The latest clear consumer-access change came on May 22, when the FDA approved an over-the-counter adapalene and benzoyl peroxide gel for people age 12 and older. "Over the counter," or OTC, means the product does not require a prescription.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What actually changed for consumers?
- Which treatments still have the strongest support?
- Does the new isotretinoin evidence change dosing?
- What should readers watch next?
What actually changed for consumers?
The FDA's updated switch list records the May 22 approval of OTC Differin Epiduo acne Gel, containing adapalene 0.1% and benzoyl peroxide 2.5%. It covers adults and children age 12 and older, according to the FDA's prescription-to-nonprescription switch list. August did not bring another documented major U.S. approval.
That distinction matters because an approval expands a recognized treatment option, while a study announcement or trial registration does not establish effectiveness. The other important regulatory development occurred July 16. An FDA warning letter found that TreeActiv and Ayadara spot treatments made "cystic," "hormonal," and "severe acne" claims that rendered them unapproved new drugs and misbranded products, as detailed in the FDA warning letter. Those findings reinforce the limits of the topical-acne monograph—the FDA framework governing permitted nonprescription acne ingredients and claims. Shoppers should not treat language about severe or hormonal acne as proof that an OTC product can manage those conditions.
Which treatments still have the strongest support?
The current American Academy of Dermatology guideline strongly recommends benzoyl peroxide, topical retinoids, antibiotics, and combination topical treatment. It advises limiting antibiotic use and pairing antibiotics with benzoyl peroxide to reduce resistance, according to the AAD's acne-management guideline summary.
The same guideline finds insufficient evidence to recommend chemical peels, lasers or light devices, microneedling, dietary changes, vitamins, or plant-based treatments for acne. "Insufficient" does not mean every approach is ineffective; it means the evidence cannot yet support a general recommendation. Readers comparing treatments can use a simple evidence check:.
- Give more weight to guideline-backed active ingredients than to claims such as "hormonal," "detoxifying," or "severe-acne relief."
- If an antibiotic is proposed, ask about the intended duration and how benzoyl peroxide fits into the plan.
- For a peel, device, vitamin, or plant-based treatment, ask for controlled acne trials that measured meaningful outcomes.
- Do not use a product's marketing language as a diagnosis of acne type or severity.
Does the new isotretinoin evidence change dosing?
A March 2026 meta-analysis included four randomized trials with 202 analyzed patients. Low-dose isotretinoin produced comparable efficacy at 24 weeks and better tolerability and satisfaction than conventional dosing. However, the authors rated the efficacy evidence as low certainty, with limited evidence for substantially severe acne. A separate single-center randomized trial compared cumulative doses of 120 and 150 mg per kilogram. Lesion improvement was similar, while 12-month relapse occurred in 26.7% and 32.3% of participants, respectively; the difference was not significant.
Retrospective trial registration further limits confidence in the result. Together, these studies challenge the assumption that more isotretinoin necessarily produces better outcomes. They do not establish one ideal dose for every patient or prove that lower dosing works equally well across all acne severity levels. An August trial adds a narrower finding. Among 80 adults ages 18 to 25, 10-mg isotretinoin plus 1 gram of fish oil was noninferior to isotretinoin alone for reducing total acne counts over three months. That small, short trial does not show that fish oil improves results or justify its routine use alongside isotretinoin.
What should readers watch next?
Denifanstat is an experimental oral drug that inhibits fatty acid synthase. In a Phase 2 trial, it reduced total lesions more than placebo at 12 weeks, but the key comparison for at least a two-grade improvement in Investigator's Global Assessment was not significant. That assessment is a clinician-rated measure of overall acne severity. A planned U.S. Phase 3 program remained subject to clearance of an Investigational New Drug application.
Useful future evidence would need to confirm improvement across both lesion counts and broader clinician-rated severity measures. The August-specific pipeline event was the August 1 registration in Japan of a 30-person AviClear study. The open-label, randomized half-face trial will compare AviClear plus standard therapy, but it is still recruiting and has no published results, according to the UMIN Clinical Trials Registry entry. A registered study shows that researchers intend to test a treatment; it does not show that the treatment works. Until results are published, the AviClear trial should remain a watch item rather than a reason to change treatment.